Human Parvovirus

Infectious Diseases of the Fetus and Newborn Infant

Volumn , Issue , 2011, Pages 834-860

  Adler, Stuart P ^a   Koch, William C ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856620076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6400-8.00027-4     Document Type: Chapter

References (344)

1. Allander T., et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12891-12896.
2. Kesebir D., et al. Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J. Infect. Dis. 2006, 194:1276-1282.
3. Virus Taxonomy 1995, Springer-Verlag, New York. F.A. Murphy (Ed.).
4. Young N.S., Brown K.E. Parvovirus B19. N. Engl. J. Med. 2004, 350:586-597.
5. Koch W.C. Fifth (human parvovirus B19) and sixth (herpesvirus 6) diseases. Curr. Opin. Infect. Dis. 2001, 14:343-356.
6. Cossart Y.E., et al. Parvovirus-like particles in human sera. Lancet 1975, 1:72-73.
7. Summers J., Jones S.E., Anderson M.J. Characterization of the genome of the agent of erythrocyte aplasia permits its classification as a human parvovirus. J. Gen. Virol. 1983, 64:2527.
8. Pattison J.R., Jones S.E., Hodgson J. Parvovirus infections and hypoplastic crisis in sickle-cell anemia (letter). Lancet 1981, 1:664-665.
9. Serjeant G.R., et al. Outbreak of aplastic crises in sickle cell anemia associated with parvovirus-like agent. Lancet 1981, 2:595-597.
10. Anderson M.J., et al. Human parvovirus, the cause of erythema infectiosum (fifth disease) (letter). Lancet 1983, 1:1378.
11. Thurn J. Human parvovirus B19: historical and clinical review. Rev. Infect. Dis. 1988, 10:1005-1011.
12. Ager E.A., Chin T.D.Y., Poland J.D. Epidemic erythema infectiosum. N. Engl. J. Med. 1966, 275:1326.
13. Cramp J.E., Armstrong B.D.J. Erythema infectiosum: no evidence of teratogenicity. BMJ 1977, 2:1031.
14. Pattison J.R. B19 virus infections in pregnancy. Parvoviruses and Human Disease 1988, CRC Press, Boca Raton, FL. J.R. Pattison (Ed.).
15. Siegel G. Patterns of parvovirus disease in animals. Parvoviruses and Human Disease 1988, CRC Press, Boca Raton, FL. J.R. Pattison (Ed.).
16. Brown T., et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984, 2:1033.
17. Knott P.D., Welply G.A.C., Anderson M.J. Serologically proved intrauterine infection with parvovirus (letter). BMJ 1984, 289:1960.
18. Anand A., et al. Human parvovirus infection in pregnancy and hydrops fetalis. N. Engl. J. Med. 1987, 316:183.
19. Kinney J.S., et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J. Infect. Dis. 1988, 157:663.
20. Hall S.M. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 1990, 300:1166-1170.
21. Adler S.P., et al. Risk of human parvovirus B19 infections among school and hospital employees during endemic periods. J. Infect. Dis. 1993, 168:361.
22. Gratacos E., et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J. Infect. Dis. 1995, 171:1360-1363.
23. Koch W.C., et al. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B10 with a primary maternal infection during pregnancy. Pediatr. Infect. Dis. J. 1998, 17:489-494.
24. Pringle C.R. Virus taxonomy update. Arch. Virol. 1993, 133:491-495.
25. Astell C.R., et al. B19 parvovirus: biochemical and molecular features. Monographs in Virology 1997, vol. 20. Karger, Basel, Human Parvovirus B19. L.J. Anderson, N.S. Young (Eds.).
26. O'Sullivan M.G., Anderson D.C., Fikes J.D., Bain F.T., Carlson C.S., Green S.W., et al. Identification of a novel simian parvovirus from cynomolgus monkey with severe anemia: a paradigm for human B19 parvovirus infection. J. Clin. Invest. 1994, 93:1571-1576.
27. Mori J., Beattie P., Melton D.W., Cohen B.J., Clewley J.P. Structure and mapping the DNA of human parvovirus B19. J. Gen. Virol. 1987, 68:2797-2806.
28. Umene K., Nunoue T. Genetic diversity of human parvovirus B19 determined using a set of restriction endonucleases recognizing four or five base pairs and partial nucleotide sequencing: use of sequence variability in virus classification. J. Gen. Virol. 1997, 72:1991.
29. Gallinella G., et al. B19 virus genome diversity: epidemiological and clinical correlations. J. Clin. Virol. 2003, 76:9124-9134.
30. Nguyen Q.T., et al. Novel human erythrovirus associated with transient aplastic crisis. J. Clin. Micro. 1999, 37:2483-2487.
31. Nguyen Q.T., et al. Identification and characterization of a second human erythrovirus variant, A6. Virology 2002, 30:374-380.
32. Servant A., et al. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 2002, 76:9124-9134.
33. Brown C.S., et al. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J. Virol. 1991, 65:2702-2706.
34. Kajigay S., et al. Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:4646-4650.
35. Ozawa K., et al. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J. Virol. 1988, 62:2884-2889.
36. Moffat S., et al. Human parvovirus B19 nonstructural protein NS1 induces apoptosis in erythroid lineage cells. J. Virol. 1998, 72:3018-3028.
37. Sol N., et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by parvovirus B19. J. Virol. 1999, 73:8762-8770.
38. Ozawa K., Kurtzman G., Young N. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 1986, 233:883-886.
39. Srivastava A., Lu L. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells form normal human bone marrow. J. Virol. 1988, 62:3059-3063.
40. Yaegashi N., et al. Propagation of human parovirus B19 in primary culture of erythroid lineage cells derived from fetal liver. J. Virol. 1989, 63:2422-2426.
41. Takahahsi T., et al. B19 parvovirus replicates in erythroid leukemic cells in vitro. J. Infect. Dis. 1989, 160:548-549.
42. Miyagawa E., et al. Infection of the erythroid cell line KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J. Virol. Methods 1999, 83:45-54.
43. Brown K.E., Young N.S., Liu J.M. Molecular, cellular and clinical aspects of parvovirus B19 infection. Crit. Rev. Oncol. Hematol. 1994, 16:1-31.
44. Brown K.E., Anderson S.M., Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262:114-117.
45. Brown K.E., et al. Resistance to parvovirus B19 infection due to a lack of virus receptor (erythrocyte P antigen). N. Engl. J. Med. 1994, 330:1192-1196.
46. Weigel-Kelley K.A., Yoder M.C., Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J. Virol. 2001, 75:4110-4116.
47. Weigel-Kelley K.A., Yoder M.C., Srivastava A. Alpha5 beta 1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta 1 integrin for viral entry. Blood 2003, 102:3927-3933.
48. Brown K.E., Young N.S. Parvovirus B19 infection and hematopoiesis. Blood Rev. 1995, 9:176-182.
49. Young N. Hematologic and hematopoietic consequences of B19 infection. Semin. Hematol. 1988, 25:159-172.
50. Srivastava A., et al. Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 1990, 76:1997-2004.
51. Anderson M.J., et al. Experimental parvovirus infection in humans. J. Infect. Dis. 1985, 152:257-265.
52. Moffat S., et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J. Virol. 1996, 70:8485-8491.
53. Gilbert N.L., et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol. Infect. 2005, 133:299-304.
54. Teuscher T., Baillod B., Holzer B.R. Prevalence of human parvovirus B19 in sickle cell disease and healthy controls. Trop. Geogr. Med. 1991, 43:108.
55. Schwarz T.F., et al. Seroprevalence of human parvovirus B19 infection in São Tomé and Principe, Malawi and Mascarene Islands. Int. J. Med. Microbiol. 1989, 271:231.
56. Jones P.H., et al. Human parvovirus infection in children and severe anaemia seen in an area endemic for malaria. J. Trop. Med. Hyg. 1990, 93:67.
57. de Freitas R.B., et al. Prevalence of human parvovirus (B19) and rubellavirus infections in urban and remote rural areas in northern Brazil. J. Med. Virol. 1990, 32:203.
58. Gaggero A., et al. Seroprevalence of IgG antibodies against parvovirus B19 among blood donors from Santiago, Chile. Rev. Med. Chil. 2007, 135:443-448.
59. Rohrer C., et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol. Infect. 2008, 16:1-12.
60. Brown C.S., et al. Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle. J. Virol. 1992, 66:69-89.
61. Morey A.L., et al. Immunohistological detection of human parvovirus B19 in formalin-fixed, paraffin-embedded tissues. J. Pathol. 1992, 166:105.
62. Loughrey A.C., et al. Identification and use of a neutralizing epitope of parvovirus B19 for the rapid detection of virus infection. J. Med. Virol. 1993, 39:97.
63. Morinet F., et al. Comparison of 17 isolates of the human parvovirus B19 by restriction enzyme analysis. Arch. Virol. 1986, 90:165.
64. Umene K., Nunoue T. The genome type of human parvovirus B19 strains isolated in Japan during 1981 differs from types detected in 1986 to 1987: a correlation between genome type and prevalence. J. Gen. Virol. 1990, 71:983.
65. Umene K., Nunoue T. Partial nucleotide sequencing and characterization of human parvovirus B19 genome DNAs from damaged human fetuses and from patients with leukemia. J. Med. Virol. 1993, 39:333.
66. Lawton A.L., Smith R.E. Erythema infectiosum: a clinical study of an epidemic in Branford, Connecticut. Arch. Intern. Med. 1931, 47:28.
67. Chargin L., Sobel N., Goldstein H. Erythema infectiosum: report of an extensive epidemic. Arch. Dermatol. Syphilol. 1943, 47:467.
68. Galvon F.A.C. An outbreak of erythema infectiosum-Nova Scotia. Can. Dis. Wkly. Rep. 1983, 9:69.
69. Serjeant G.R., et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993, 341:1237.
70. Oliveira S.A., et al. Clinical and epidemiological aspects of human parvovirus B19 infection in an urban area in Brazil (Niteroi city area, State of Rio de Janeiro, Brazil). Mem. Inst. Oswaldo Cruz 2002, 97:965-970.
71. Yamashita K., et al. A significant age shift of the human parvovirus B19 antibody prevalence among young adults in Japan observed in a decade. Jpn. J. Med. Sci. Biol. 1992, 45:49.
72. Naides S.J. Erythema infectiosum (fifth disease) occurrence in Iowa. Am. J. Public Health 1988, 78:1230.
73. Cohen B.J., Buckley M.M. The prevalence of antibody to human parvovirus B19 in England and Wales. J. Med. Microbiol. 1988, 25:151.
74. Nascimento J.P., et al. The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil. Rev. Inst. Med. Trop. São Paulo 1990, 32:41.
75. Edelson R.N., Altman R.A. Erythema infectiosum: a statewide outbreak. J. Med. Soc. N. J. 1970, 67:805.
76. Werner G.H., et al. A new viral agent associated with erythema infectiosum. Ann. N. Y. Acad. Sci. 1957, 67:338.
77. Greenwald P., Bashe W.J. An epidemic of erythema infectiosum. Am. J. Dis. Child. 1964, 107:30.
78. Yaegashi N., et al. Prevalence of anti-human parvovirus antibody in pregnant women. Nippon Sanka Fujinka Gakkai Zasshi 1990, 42:162.
79. Koch W.C., Adler S.P. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr. Infect. Dis. J. 1989, 8:83.
80. Cohen B.J., Mortimer P.P., Pereira M.S. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J. Hyg. (Lond.) 1983, 91:113.
81. Schwarz T.F., Roggendorf M., Deinhardt F. Häufigkeit der parovirus-B19-infektionen. Seroepidemiologishe untersuchungen. Dtsch. Med. Wochenschr. 1987, 112:1526.
82. Bartolomei Corsi O., et al. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J. Med. Virol. 1988, 25:165.
83. Eiffert H., et al. Expression of an antigenic polypeptide of the human parvovirus B19. Med. Microbiol. Immunol. 1990, 179:169.
84. Brown C.S., et al. An immunofluorescence assay for the detection of parvovirus B19 IgG and IgM antibodies based on recombinant viral antigen. J. Virol. Methods 1990, 29:53.
85. Rollag H., et al. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand. J. Infect. Dis. 1991, 23:675.
86. Salimans M.M.M., et al. Recombinant parvovirus B19 capsids as a new substrate for detection of B19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assay. J. Virol. Methods 1992, 39:247.
87. Schwarz T.F., Hottenträger B., Roggendorf M. Prevalence of antibodies to parvovirus B19 in selected groups of patients and healthy individuals. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 1992, 276:437.
88. Vyse A.J., Andrews N.J., Hesketh L.M. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol. Infect. 2007, 135:1354-1362.
89. Lin K.H., et al. Seroepidemiology of human parvovirus B19 in Taiwan. J. Med. Virol. 1999, 57:169-173.
90. Couroucé A.M., et al. Parvovirus (SPLV) et antigène Aurillac. Rev. Fr. Transfus. Immunohematol. 1984, 27:5.
91. Cossart Y. Parvovirus B19 finds a disease (letter). Lancet 1981, 2:988.
92. O'Neill H.J., Coyle P.V. Two anti-parvovirus B19 IgM capture assays incorporating a mouse monoclonal antibody specific for B19 viral capsid proteins VP1 and VP2. Arch. Virol. 1992, 123:125.
93. Cohen B.J., et al. Blood donor screening for parvovirus B19. J. Virol. Methods 1990, 30:233.
94. da Silva Cruz A., et al. Detection of the human parvovirus B19 in a blood donor plasma in Rio de Janeiro. Mem. Inst. Oswaldo Cruz 1989, 84:279.
95. McOmish F., et al. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J. Clin. Microbiol. 1993, 31:323.
96. Yaegashi N., et al. Enzyme-linked immunosorbent assay for IgG and IgM antibodies against human parvovirus B19: use of monoclonal antibodies and viral antigen propagated in vitro. J. Virol. Methods 1989, 26:171.
97. Naides S.J., et al. Rheumatologic manifestations of human parvovirus B19 infection in adults. Arthritis Rheum. 1990, 33:1297.
98. Martinez-Campillo F., et al. Parvovirus B19 outbreak in a rural community in Alicante. Enferm. Infecc. Microbiol. Clin. 2002, 20:376-379.
99. Abarca K., Cohen B.J., Vial P.A. Seroprevalence of parvovirus B19 in urban Chilean children and young adults, 1990 and 1996. Epidemiol. Infect. 2002, 128:59-62.
100. Smith-Whitley K., et al. The epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2003, 103:422.
101. Plummer F.A., et al. An erythema infectiosum-like illness caused by human parvovirus infection. N. Engl. J. Med. 1985, 313:74.
102. Chorba T., et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J. Infect. Dis. 1986, 154:383-393.
103. Mortimer P.P. Hypothesis: the aplastic crisis of hereditary spherocytosis is due to a single transmissible agent. J. Clin. Pathol. 1983, 36:445.
104. Saarinen U.A., et al. Human parvovirus B19 induced epidemic red-cell aplasia in patients with hereditary hemolytic anemia. Blood 1986, 67:1411.
105. Valeur-Jensen A., et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999, 281:1099-1105.
106. Anderson M.J., et al. An outbreak of erythema infectiosum associated with human parvovirus infection. J. Hyg. (Lond.) 1984, 93:85.
107. Tuckerman J.G., Brown T., Cohen B.J. Erythema infectiosum in a village primary school: clinical and virological studies. J. R. Coll. Gen. Pract. 1986, 36:267.
108. Morgan-Capner P., et al. Sex ratio in outbreaks of parvovirus B19 infection (letter). Lancet 1987, 2:98.
109. Mansfield F. Erythema infectiosum: slapped face disease. Aust. Fam. Physician 1988, 17:737.
110. Woolf A.D., et al. Clinical manifestations of human parvovirus B19 in adults. Arch. Intern. Med. 1989, 149:1153.
111. Turner A., Olojugba O. Erythema infectiosum in a primary school: investigation of an outbreak in Bury. Public Health 1989, 103:391.
112. Grilli E.A., Anderson M.J., Hoskins T.W. Concurrent outbreaks of influenza and parvovirus B19 in a boys' boarding school. Epidemiol. Infect. 1989, 103:359.
113. Gillespie S.M., et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990, 263:2061.
114. Anderson L.J., et al. Risk of infection following exposures to human parvovirus B19. Behring Inst. Mitt. 1990, 85:60.
115. Rice P.S., Cohen B.J. A school outbreak of parvovirus B19 infection investigated using salivary antibody assays. Epidemiol. Infect. 1996, 6:331-338.
116. Bell L.M., et al. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N. Engl. J. Med. 1989, 321:485.
117. Pillay D., et al. Parvovirus B19 outbreak in a children's ward. Lancet 1992, 339:107.
118. Cohen B.J., et al. Laboratory infection with parvovirus B19 (letter). J. Clin. Pathol. 1988, 41:1027.
119. Shiraishi H., et al. Laboratory infection with human parvovirus B19 (letter). J. Infect. 1991, 22:308.
120. Evans J.P.M., et al. Human parvovirus aplasia: case due to cross infection in a ward. BMJ 1984, 288:681.
121. Ueda K., et al. Human parvovirus infection (letter). N. Engl. J. Med. 1986, 314:645.
122. Pillay D., et al. Secondary parvovirus B19 infection in an immunocompromised child. Pediatr. Infect. Dis. J. 1991, 10:623.
123. Lui S.L., et al. Nosocomial outbreak of parvovirus B19 infection in a renal transplant unit. Transplantation 2001, 71:59-64.
124. Miyamoto K., et al. Outbreak of human parvovirus B19 in hospital workers. J. Hosp. Infect. 2000, 45:238-241.
125. Koziol D.E., et al. Nosocomial human parvovirus B19 infection: lack of transmission from a chronically infected patient to hospital staff. Infect. Control Hosp. Epidemiol. 1992, 13:343.
126. Dowell S.F., et al. Parvovirus B19 infection in hospital workers. Community or hospital acquisition. J. Infect. Dis. 1995, 172:1076-1079.
127. Carter M.L., et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J. Infect. Dis. 1991, 163:282.
128. Ray S.M., et al. Nosocomial exposure to parvovirus B19: low risk of transmission to healthcare workers. Infect. Control Hosp. Epidemiol. 1997, 18:109-114.
129. Patou G., et al. Characterization of a nested polymerase chain reaction assay for detection of parvovirus B19. J. Clin. Microbiol. 1993, 31:540.
130. Potter C.G., et al. Variation of erythroid and myeloid precursors in the marrow of volunteer subjects infected with human parvovirus (B19). J. Clin. Invest. 1987, 79:1486.
131. Morey A.L., et al. Non-isotopic in situ hybridisation and immunophenotyping of infected cells in investigation of human fetal parvovirus infection. J. Clin. Pathol. 1992, 45:673-678.
132. Mortimer P.P., et al. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet 1983, 2:482.
133. Lyon D.J., et al. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate (letter). Lancet 1989, 1:1085.
134. Williams M.D., et al. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang. 1990, 58:177.
135. Morfini M., et al. Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus (letter). Am. J. Hematol. 1992, 39:149.
136. Zakrzewska K., et al. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction. Br. J. Haematol. 1992, 81:407.
137. Schwarz T.F., et al. Removal of parvovirus B19 from contaminated factor VIII during fractionation. J. Med. Virol. 1991, 35:28.
138. Azzi A., et al. Human parvovirus B19 infection in hemophiliacs infused with two high purity, virally attenuated factor VIII concentrates. Am. J. Hematol. 1992, 39:228.
139. Anderson M.J. Rash illness due to B19 virus. Parvoviruses and Human Disease 1988, CRC Press, Boca Raton, FL. J.R. Pattison (Ed.).
140. Anderson L.J. Role of parvovirus B19 in human disease. Pediatr. Infect. Dis. 1987, 6:711-718.
141. Garcia-Tapia A.M., et al. Spectrum of parvovirus B19 infection: analysis of an outbreak of 43 cases in Cadiz, Spain. Clin. Infect. Dis. 1995, 21:424-430.
142. Zerbini M., et al. Different syndromes associated with B19 parvovirus viraemia in paediatric patients: report of four cases. Eur. J. Pediatr. 1992, 151:815-817.
143. Tsuda H., Maeda Y., Nakagawa K. Parvovirus B19-related lymphadenopathy. Br. J. Haematol. 1993, 85:631-632.
144. Brown K.E. Human parvovirus B19 epidemiology and clinical manifestations. Monographs in Virology 1997, vol. 20:42-60. Karger, Basel. L.J. Anderson, N.S. Young (Eds.).
145. Lefrere J.J., et al. Henoch-Schonlein purpura and human parvovirus infection. Pediatrics 1986, 78:183-184.
146. Saunders P.W., Reid M.M., Cohen B.J. Human parvovirus induced cytopenias: a report of five cases. Br. J. Haematol. 1986, 63:407-410.
147. Lefrere J.J., Courouce A.M., Kaplan C. Parvovirus and idiopathic thrombocytopenic purpura (letter). Lancet 1989, 1:279.
148. Török T.J. Parvovirus B19 and human disease. Adv. Int. Med. 1992, 37:431-455.
149. White D.G., et al. Human parvovirus arthropathy. Lancet 1985, 1:419-421.
150. Naides S.J., Field E.H. Transient rheumatoid factor positivity in acute human parvovirus B19 infection. Arch. Intern. Med. 1988, 148:2587-2589.
151. Reid D.M., et al. Human parvovirus-associated with arthritis: a clinical and laboratory description. Lancet 1985, 1:422-425.
152. Nocton J.J., et al. Human parvovirus B19-associated arthritis in children. J. Pediatr. 1993, 122:186-190.
153. Dijkmans B.A., et al. Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum. 1998, 31:279-281.
154. Saal J.G., et al. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatology 1992, 12:147-151.
155. Mimori A., et al. Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis. Rheumatol. Int. 1994, 14:87-90.
156. Soderlund M., et al. Persistence of parvovirus B19 DNA in synovial membranes of young patients with and without chronic arthropathy. Lancet 1997, 349:1063-1065.
157. Stahl H.D., et al. Detection of multiple viral DNA species in synovial tissue and fluid of patients with early arthritis. Ann. Rheum. Dis. 2000, 59:342-346.
158. Kerr J.R. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 2000, 59:672-683.
159. Koch W.C., et al. Manifestations and treatment of human parvovirus B19 infection in immunocompromised patients. J. Pediatr. 1990, 116:355-359.
160. Van Horn D.K., et al. Human parvovirus-associated red cell aplasia in the absence of hemolytic anemia. Am. J. Pediatr. Hematol-Oncol. 1986, 8:235-239.
161. Kurtzman G.J., et al. Chronic bone marrow failure due to persistent B19 parvovirus infection. N. Engl. J. Med. 1987, 317:287-294.
162. Frickhofen N., et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann. Intern. Med. 1990, 113:926-933.
163. Weiland H.T., et al. Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant recipient (letter). Br. J. Haematol. 1989, 71:300.
164. Kurtzman G., et al. Pure red-cell aplasia of ten years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N. Engl. J. Med. 1989, 321:519-523.
165. Wong T.Y., et al. Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus. Am. J. Kidney Dis. 1999, 34:1119-1123.
166. Geetha D., et al. Pure red cell aplasia caused by parvovirus B19 infection in solid organ transplant recipients: a case report and review of the literature. Clin. Transplant. 2000, 14:586-591.
167. Pamidi S., et al. Human parvovirus infection presenting as persistent anemia in renal transplant recipients. Transplantation 2000, 69:2666-2669.
168. Zolnourian Z.R., et al. Parvovirus B19 in kidney transplant patients. Transplantation 2000, 69:2198-2202.
169. Seishima M., Kanoh H., Izumi T. The spectrum of cutaneous eruptions in 22 patients with isolated serological evidence of infection by parvovirus B19. Arch. Dermatol. 1999, 135:1556-1557.
170. Lefrere J.J., et al. Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am. J. Hematol. 1986, 23:271-275.
171. Finkel T.H., et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis. Opportunistic infeciton or aetiological agent. Lancet 1994, 343:1255-1258.
172. Schwarz T.F., Wiersbitzky S., Pambor M. Case report: detection of parvovirus B19 in skin biopsy of a patient with erythema infectiosum. J. Med. Virol. 1994, 43:171-174.
173. Magro C.M., Dawood M.R., Crowson A.N. The cutaneous manifestations of human parvovirus B19 infection. Hum. Pathol. 2000, 31:488-497.
174. Ferguson P.J., et al. Prevalence of human parvovirus B19 infection in children with Henoch-Schonlein purpura. Arthritis Rheum. 1996, 39:880-881.
175. Smith P.T., Landry M.L., Carey H., et al. Papular-purpuric gloves and socks syndrome associated with acute parvovirus B19 infection: case report and review. Clin. Infect. Dis. 1997, 27:164-168.
176. Grilli R., et al. Papular-purpuric "gloves and socks" syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J. Am. Acad. Dermatol. 1999, 41:793-796.
177. Saulsbury F.T. Petechial gloves and socks syndrome caused by parvovirus B19. Pediatr. Dermatol. 1998, 15:35-37.
178. Brass C., Elliott L.M., Stevens D.A. Academy rash: a probable epidemic of erythema infectiosum ("fifth disease"). JAMA 1982, 248:568-572.
179. Tsuji A., et al. Aseptic meningitis with erythema infectiosum. Eur. J. Pediatr. 1990, 149:449-450.
180. Balfour H.H., Schiff G.M., Bloom J.E. Encephalitis associated with erythema infectiosum. JAMA 1970, 77:133-136.
181. Hall C.B., Horner F.A. Encephalopathy with erythema infectiosum. Am. J. Dis. Child. 1977, 131:65-67.
182. Okumura A., Ichikawa T. Aseptic meningitis caused by human parvovirus B19. Arch. Dis. Child. 1993, 68:784-785.
183. Cassinotti P., et al. Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient. Eur. J. Clin. Microbiol. Infect. Dis. 1993, 12:701-704.
184. Watanabe T., Satoh M., Oda Y. Human parvovirus B19 encephalopathy. Arch. Dis. Child. 1994, 70:71.
185. Walsh K.J., Armstrong R.D., Turner A.M. Brachial plexus neuropathy associated with human parvovirus infection. BMJ 1988, 296:896.
186. Faden H., Gary G.W., Korman M. Numbness and tingling of fingers associated with parvovirus B19 infection. J. Infect. Dis. 1990, 161:354-355.
187. Dereure O., Montes B., Guilhou J.J. Acute generalized livedo reticularis with myasthenia-like syndrome revealing parvovirus B19 primary infection. Arch. Dermatol. 1995, 131:744-745.
188. Samii K., et al. Acute bilateral carpal tunnel syndrome associated with human parvovirus B19 infection. Clin. Infect. Dis. 1996, 22:162-164.
189. Faden H., Gary G.W., Anderson L.J. Chronic parvovirus infection in a presumably immunologically healthy woman. Clin. Infect. Dis. 1992, 15:595-597.
190. Barah F., et al. Neurological manifestations of human parvovirus B19 infection. Rev. Med. Virol. 2003, 13:185-199.
191. Nakazawa T., et al. Acute glomerulonephritis after human parvovirus B19 infection. Am. J. Kidney Dis. 2000, 35:E31.
192. Komatsuda A., et al. Endocapillary proliferative glomerulonephritis in a patient with parvovirus B19 infection. Am. J. Kidney Dis. 2000, 36:851-854.
193. Diaz F., Collazos J. Glomerulonephritis and Henoch-Schoenlein purpura associated with acute parvovirus B19 infection. Clin. Nephrol. 2000, 53:237-238.
194. Tanawattanacharoen S., et al. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am. J. Kidney Dis. 2000, 35:1166-1174.
195. Klein R.M., et al. Frequency and quantity of the parvovirus B19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z. Kardiol. 2004, 93:300-309.
196. Munro K., et al. Three cases of myocarditis in childhood associated with human parvovirus (B19 virus). Pediatr. Cardiol. 2003, 24:473-475.
197. Lamparter S., et al. Acute parvovirus B19 infection associated with myocarditis in an immunocompetent adult. Hum. Pathol. 2003, 34:725-728.
198. Wang X., et al. Prevalence of human parvovirus B19 DNA in cardiac tissues of patients with congenital heart diseases indicated by nested PCR and in situ hybridization. J. Clin. Virol. 2004, 31:20-24.
199. Bultmann B.D., et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am. J. Obstet. Gynecol. 2006, 195:330-331.
200. Kuhl U., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005, 112:1965-1970.
201. Kuethe F., et al. Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy. Am. Heart J. 2007, 153:850-858.
202. Tavora F., et al. Fatal parvoviral myocarditis: a case report and review of literature. Diagn. Pathol. 2008, 3:21.
203. Marton T., Martin W.L., Whittle M.J. Hydrops fetalis and neonatal death from human parvovirus B19: an unusual complication. Prenat. Diagn. 2005, 7:543-545.
204. Nyman M., Skjoldebrand-Sparre L., Broliden K. Non-hydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. J. Perinat. Med. 2005, 33:176-178.
205. Anderson L.J., et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 1986, 24:522.
206. Cohen B.J., Bates C.M. Evaluation of 4 commercial test kits for parvovirus B19-specific IgM. J. Virol. Methods 1995, 55:11-25.
207. Koch W.C. A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays. J. Virol. Methods 1995, 55:67-82.
208. Jordan J.A. Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women. J. Clin. Microbiol. 2000, 38:1472-1475.
209. Doyle S., et al. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristics analysis. J. Virol. Methods 2000, 90:143-152.
210. Clewly J.P. Detection of human parvovirus using a molecularly cloned probe. J. Med. Virol. 1985, 15:383-393.
211. Clewly J.P. Polymerase chain reaction assay of parvovirus B19 DNA in clinical specimens. J. Clin. Microbiol. 1989, 27:2647.
212. Koch W.C., Adler S.P. Detection of human parvovirus B19 DNA by using the polymerase chain reaction. J. Clin. Microbiol. 1990, 28:65-69.
213. Heegard E.D., et al. Parvovirus B19 infection and Diamond-Blackfan anemia. Acta Pediatr. 1996, 85:299-302.
214. Crook T.W., et al. Unusual bone marrow manifestations of parvovirus B19 infection in immunocompromised patients. Hum. Pathol. 2000, 31:161-168.
215. Adler S.P., Harger J.H., Koch W.C. Infections due to human parvovirus B19 during pregnancy. Infectious Diseases in Women 2001, Saunders, Philadelphia. M. Martens, S. Faro, D. Soper (Eds.).
216. van Gessel P.H., et al. Incidence of parvovirus B19 infection among an unselected population of pregnant women in the Netherlands: a prospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006, 128:46-49.
217. Mossong J., et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol. Infect. 2007, 24:1-10.
218. Enders M., Weidner A., Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol. Infect. 2007, 135:563-569.
219. Candotti D., et al. Maternal-fetal transmission of human parvovirus B19 genotype 3. J. Infect. Dis. 2006, 194:608-611.
220. Skjoldebrand-Sparre L., et al. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet. Gynecol. Scand. 1996, 75:336-339.
221. Mortimer P.P., et al. Human parvovirus and the fetus (letter). Lancet 1985, 2:1012.
222. Wiersbitzky V.S., et al. Seroprävalenz von Antikörpern gegen das humane parvovirus B19 (Ringelröteln/erythema infectiosum) in der DDR-Bevölkerung. Kinderärztl. Prax. 1990, 58:185.
223. Schoub B.D., et al. Primary and secondary infection with human parvovirus B19 in pregnant women in South Africa. S. Afr. Med. J. 1993, 83:505-506.
224. Barros De Freitas R., et al. Survey of parvovirus B19 infection in a cohort of pregnant women in Belem, Brazil. Braz. J. Infect. Dis. 1999, 3:6-14.
225. Enders G., Biber M. Parvovirus B19 infections in pregnancy. Behring Inst. Mitt. 1990, 85:74.
226. Rogers B.B., et al. Detection of human parvovirus B19 in early spontaneous abortuses using serology, histology, electron microscopy, in situ hybridization, and the polymerase chain reaction. Obstet. Gynecol. 1993, 81:402.
227. Harger J.H., et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet. Gynecol. 1998, 91:413-420.
228. Kerr J.R., Curran M.D., Moore J.E. Parvovirus B19 infection-persistence and genetic variation. Scand. J. Infect. Dis. 1995, 27:551-557.
229. Chisaka H., et al. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J. Exp. Med. 2006, 209:277-283.
230. Schwarz T.F., et al. Human parvovirus B19 infection in pregnancy (letter). Lancet 1988, 2:566-567.
231. Gray E.S., Anand A., Brown T. Parvovirus infections in pregnancy (letter). Lancet 1986, 1:208.
232. Brown T., Ritchie L.D. Infection with parvovirus during pregnancy. BMJ 1985, 290:559-560.
233. Kinney J.S., et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J. Infect. Dis. 1988, 157:663-667.
234. Rodis J.F., et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am. J. Obstet. Gynecol. 1990, 163:1168.
235. Torok T.J., et al. Reproductive outcomes following human parvovirus B19 infection in pregnancy (abstract 1374). Program and Abstracts of 31st ICAAC (Chicago) 1991, American Society for Microbiology, Washington, DC.
236. Enders M., et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat. Diagn. 2004, 24:513-518.
237. Xu D., Zhang G., Wang R. The study on detection of human parvovirus B19 DNA in spontaneous abortion tissues. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1998, 12:158-160.
238. Wang R., Chen X., Han M. Relationship between human parvovirus B19 infection and spontaneous abortion. Zhonghua Fu Chan Ke Za Zhi 1997, 32:541-543.
239. De Krijger R.R., et al. Detection of parvovirus B19 infection in first and second trimester fetal loss. Pediatr. Pathol. Lab. Med. 1998, 18:23-34.
240. Makhseed M., et al. Pattern of parvovirus B19 infection during different trimesters of pregnancy in Kuwait. Infect. Dis. Obstet. Gynecol. 1997, 7:287-292.
241. Lowden E., Weinstein L. Unexpected second trimester pregnancy loss due to maternal parvovirus B19 infection. South Med. J. 1997, 90:702-704.
242. Skjoldebrand-Sparre L., et al. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. Br. J. Obstet. Gynaecol. 2000, 107:476-480.
243. Nunoue T., Kusuhara K., Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr. Infect. Dis. J. 2002, 21:1133-1136.
244. Norbeck O., et al. Revised clinical presentation of parvovirus B19-associated intrauterine fetal death. Clin. Infect. Dis. 2002, 35:1032-1038.
245. Tolfvenstam T., et al. Frequency of human parvovirus B19 infection in intrauterine fetal death. Lancet 2001, 357:1494-1497.
246. Leung T.N., et al. Fetal parvovirus B19 infection in a twin pregnancy with 1 twin presenting with hydrops fetalis and the other asymptomatic: a case report. J. Reprod. Med. 2007, 5:419-421.
247. Dickinson J.E., Keil A.D., Charles A.K. Discordant fetal infection for parvovirus B19 in a dichorionic twin pregnancy. Twin Res. Hum. Genet. 2006, 9:456-459.
248. el-Sayed Zaki M., Goda H. Relevance of parvovirus B19, herpes simplex virus 2, and cytomegalovirus virologic markers in maternal serum for diagnosis of unexplained recurrent abortions. Arch. Pathol. Lab. Med. 2007, 131:956-960.
249. Kishore J., Gupta I. Serological study of parvovirus B19 infection in women with recurrent spontaneous abortions. Indian J. Pathol. Microbiol. 2006, 49:548-550.
250. Koch W.C., Adler S.P., Harger J. Intrauterine parvovirus B19 infection may cause an asymptomatic or recurrent postnatal infection. Pediatr. Infect. Dis. J. 1993, 12:747-750.
251. Weiland H.T., et al. Parvovirus B19 associated with fetal abnormality (letter). Lancet 1987, 1:682.
252. Hartwig N.G., et al. Embryonic malformations in a case of intrauterine parvovirus B19 infection. Teratology 1989, 39:295.
253. Hartwig N.G., Vermeij-Keers C., Versteeg J. The anterior eye segment in virus induced primary congenital aphakia. Acta Morphol. Neerl. Scand. 1988-1989, 26:283.
254. Zerbini M., et al. Symptomatic parvovirus B19 infection of one fetus in a twin pregnancy. Clin. Infect. Dis. 1993, 17:262.
255. Morey A.L., et al. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br. J. Obstet. Gynaecol. 1992, 99:566.
256. Rodis J.F., et al. Human parvovirus infection in pregnancy. Obstet. Gynecol. 1988, 72:733.
257. Naides S.J., Weiner C.P. Antenatal diagnosis and palliative treatment of non-immune hydrops fetalis secondary to fetal parvovirus B19 infection. Prenat. Diagn. 1989, 9:105.
258. Katz V.L., Chescheir N.C., Bethea M. Hydrops fetalis from B19 parvovirus infection. J. Perinatol. 1990, 10:366.
259. Bloom M.C., et al. Infection materno-foetale à parvovirus associée à une péritonite meconiale anétnatale. Arch. Fr. Pediatr. 1990, 47:437.
260. Bernard J.D., et al. Infection materno-foetale à parvovirus humain B19: a propos de deux observations. J. Gynecol. Obstet. Biol. Reprod. 1991, 20:855.
261. Schwarz T.F., et al. Parvovirus B19 infection of the fetus: histology and in situ hybridization. Am. J. Clin. Pathol. 1991, 96:121.
262. Rodis J.F., et al. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet. Gynecol. 1998, 91:125-128.
263. Jouannic J.M., et al. Isolated fetal hyperechogenic bowel associated with intrauterine parvovirus B19 infection. Fetal Diagn. Ther. 2005, 20:498-500.
264. Porter H.J., et al. Parvovirus as a cause of hydrops fetalis: detection by in situ DNA hybridisation. J. Clin. Pathol. 1988, 41:381-383.
265. Yaegashi N., et al. The frequency of human parvovirus B19 infection in nonimmune hydrops fetalis. J. Perinat. Med. 1994, 22:159-163.
266. Gloning K.P., et al. Successful intrauterine treatment of fetal hydrops caused by parvovirus B19 infection. Behring Inst. Mitt. 1990, 85:79.
267. Rogers B.B., Mark Y., Oyer C.E. Diagnosis and incidence of fetal parvovirus infection in an autopsy series. I. Histology. Pediatr. Pathol. 1993, 13:371.
268. Mark Y., Rogers B.B., Oyer C.E. Diagnosis and incidence of fetal parvovirus infection in an autopsy series. II. DNA amplification. Pediatr. Pathol. 1993, 13:381.
269. Peters M.T., Nicolaides K.H. Cordocentesis for the diagnosis and treatment of human fetal parvovirus infection. Obstet. Gynecol. 1990, 75:501.
270. Pryde P.G., et al. Spontaneous resolution of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Obstet. Gynecol. 1992, 79:859.
271. Metzman R., et al. Hepatic disease associated with intrauterine parvovirus B19 infection in a newborn premature infant. J. Pediatr. Gastroenterol. Nutr. 1989, 9:112.
272. Franciosi R.A., Tattersall P. Fetal infection with human parvovirus B19. Hum. Pathol. 1988, 19:489.
273. Zerbini M., et al. Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydrops. J. Clin. Microbiol. 1996, 34:603-608.
274. Lewis D.B., Wilson C.B. Developmental immunology and role of host defenses in neonatal susceptibility to infection. Infectious Diseases of the Fetus and Newborn Infant 1995, Saunders, Philadelphia. fourth ed. J.S. Remington, J.O. Klein (Eds.).
275. Török T.J., et al. Prenatal diagnosis of intrauterine infection with parvovirus B19 by the polymerase chain reaction technique. Clin. Infect. Dis. 1992, 14:149.
276. Morey A.L., et al. In vitro culture for the detection of infectious human parvovirus B19 and B19-specific antibodies using foetal haematopoietic precursor cells. J. Gen. Virol. 1992, 73:3313.
277. de Haan T.R., et al. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. Br. J. Obstet. Gynaecol. 2008, 115:76-81.
278. Carrington D., et al. Maternal serum alpha-fetoprotein-a marker of fetal aplastic crisis during intrauterine human parvovirus infection. Lancet 1987, 1:433-435.
279. Anderson M.J., et al. Human parvovirus B19 and hydrops fetalis (letter). Lancet 1988, 1:535.
280. Sahakian V., et al. Intrauterine transfusion treatment of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Am. J. Obstet. Gynecol. 1991, 164:1090.
281. Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells (letter). Lancet 1988, 1:535.
282. Nerlich A.G., et al. Pathomorphologie der fetalen parvovirus-B19-infektion. Pathologe 1991, 12:204.
283. Berry P.J., et al. Parvovirus infection of the human fetus and newborn. Semin. Diagn. Pathol. 1992, 9:4.
284. Caul E.O., Usher M.J., Burton P.A. Intrauterine infection with human parvovirus B19: a light and electron microscopy study. J. Med. Virol. 1988, 24:55.
285. Maeda H., et al. Nonimmunologic hydrops fetalis resulting from intrauterine human parvovirus B19 infection: report of 2 cases. Obstet. Gynecol. 1988, 71:482-485.
286. van Elsacker-Niele A.M.W., et al. Fetal pathology in human parvovirus B19 infection. Br. J. Obstet. Gynaecol. 1989, 96:768.
287. Bonneau D., et al. L'infection à parvovirus B19 au cours de la grossesse. J. Gynecol. Obstet. Biol. Reprod. 1991, 20:1109.
288. Glaser C., Tannenbaum J. Newborn with hydrops and a rash. Pediatr. Infect. Dis. J. 1992, 11:980-984.
289. Nerlich A., et al. Parvovirus B19-infected erythroblasts in fetal cord blood (letter). Lancet 1991, 337:310.
290. Morey A.L., Fleming K.A. Immunophenotyping of fetal hematopoietic cells permissive for human parvovirus B19 replication in vitro. Br. J. Haematol. 1992, 82:302.
291. Jordan J.A., DeLoia J.A. Globoside expression within the human placenta. Placenta 1999, 20:103-108.
292. Jordan J.A., Huff D., DeLoia J.A. Placental cellular immune response in women infected with human parvovirus B19 during pregnancy. Clin. Diagn. Lab. Immunol. 2001, 8:288-292.
293. Brown K.E. Human parvovirus B19 infections in infants and children. Adv. Pediatr. Infect. Dis. 1998, 13:101-126.
294. Heegaard E.D., Hornsleth A. Parvovirus: the expanding spectrum of disease. Acta Paediatr. 1995, 84:109-117.
295. Respondek M., et al. Parvovirus particles in a fetal heart with myocarditis: ultrastructural and immunohistochemical study. Arch. Immunol. Ther. Exp. (Warsz) 1997, 45:465-470.
296. Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells. Lancet 1988, 535-536.
297. Nigro G., et al. Acute and chronic lymphocytic myocarditis in infancy is associated with parvovirus B19 infection and high cytokine levels. Clin. Infect. Dis. 2000, 31:65-69.
298. Heegaard E.D., et al. Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand. J. Infect. Dis. 1998, 30:607-610.
299. Papadogiannakis N., et al. Active, fulminant, lethal myocarditis associated with parvovirus B19 infection in an infant. Clin. Infect. Dis. 2002, 35:1027-1031.
300. Kovacs B.W., et al. Prenatal diagnosis of human parvovirus B19 in nonimmune hydrops fetalis by polymerase chain reaction. Am. J. Obstet. Gynecol. 1992, 167:461-466.
301. Wang X., et al. Investigation of parvovirus B19 in cardiac tissue from patients with congenital heart disease. Chin. Med. J. (Engl.) 1999, 112:995-997.
302. Conry J.A., Török T., Andrews P.I. Perinatal encephalopathy secondary to in utero human parvovirus B-19 (HPV) infection (abstract 736S). Neurology 1993, 43(Suppl.):A346.
303. Plachouras N., et al. Severe nonimmune hydrops fetalis and congenital corneal opacification secondary to human parvovirus B19 infection. A case report. J. Reprod. Med. 1999, 44:377-380.
304. Enders M., et al. Human parvovirus B19 infection during pregnancy-value of modern molecular and serological diagnostics. J. Clin. Virol. 2006, 35:400-406.
305. Enders M., et al. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J. Infect. Dis. 2008, 197:58-62.
306. Sheikh A.U., Ernest J.M., O'Shea M. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am. J. Obstet. Gynecol. 1992, 167:337.
307. de Haan T.R., et al. Parvovirus B19 infection in pregnancy studies by maternal viral load and immune responses. Fetal Diagn. Ther. 2007, 22:55-62.
308. de Haan T.R., et al. Parvovirus B19 infection in pregnancy: maternal and fetal viral load measurements related to clinical parameters. Prenat. Diagn. 2007, 27:46-50.
309. Dobec M., Juchler A., Flaviano A. Prolonged parvovirus b19 viremia in spite of neutralizing antibodies after erythema infectiosum in pregnancy. Gynecol. Obstet. Invest. 2007, 63:53-54.
310. Bernstein I.A., Capeless E.L. Elevated maternal serum alpha-fetoprotein and hydrops fetalis in association with fetal parvovirus B19 infection. Obstet. Gynecol. 1989, 774:456-457.
311. Komischke K., Searle K., Enders G. Maternal serum alpha-fetoprotein and human chorionic gonadotropin in pregnant women with acute parvovirus B19 infection with and without fetal complications. Prenat. Diagn. 1997, 17:1039-1046.
312. Kempe A., et al. First-trimester treatment of fetal anemia secondary to parvovirus B19 infection. Ultrasound Obstet. Gynecol. 2007, 29:226-228.
313. Dembinski J., et al. Neurodevelopmental outcome after intrauterine red cell transfusion for parvovirus B19-induced fetal hydrops. Br. J. Obstet. Gynaecol. 2002, 109:1232-1234.
314. Humphrey W., Magoon M., O'Shaughnessy R. Severe nonimmune hydrops secondary to parvovirus B-19 infection: spontaneous reversal in utero and survival of a term infant. Obstet. Gynecol. 1991, 78:900-902.
315. Morey A.L., et al. Parvovirus B19 infection and transient fetal ascites. Lancet 1991, 337:496.
316. Schwartz T.F., et al. Human parvovirus B19 infection in pregnancy. Lancet 1988, 2:566-567.
317. Soothill P. Intrauterine blood transfusion for non-immune hydrops fetalis due to parvovirus B19 infection. Lancet 1990, 356:121-122.
318. Sahakian V., et al. Intrauterine transfusion treatment of nonimmune hydrops fetalis secondary to human parvovirus B19 infection. Am. J. Obstet. Gynecol. 1991, 164:1090-1091.
319. Matsuda H., et al. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J. Perinat. Med 2005, 33:561-563.
320. Vogel H., et al. Congenital parvovirus infection. Pediatr. Pathol. Lab. Med. 1997, 17:903-912.
321. Torok T.T. Human parvovirus B19. Infectious Diseases of the Fetus and Newborn Infant 2001, Saunders, Philadelphia. fifth ed. J.S. Remington, J.O. Klein (Eds.).
322. Katz V.L., et al. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am. J. Perinatol. 1996, 13:43-45.
323. Enders G., et al. Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy: two case reports. Clin. Infect. Dis. 1998, 26:355-358.
324. Orth T., et al. Human parvovirus B19 infection associated with severe acute perimyocarditis in a 34-year-old man. Eur. Heart J. 1997, 18:524-525.
325. Chia J.K.S., Jackson B. Myopericarditis due to parvovirus B19 in an adult. Clin. Infect. Dis. 1996, 23:200-201.
326. Malm C., Fridell E., Jansson K. Heart failure after parvovirus B19 infection. Lancet 1993, 341:1408-1409.
327. Saint-Martin J., et al. Myocarditis caused by parvovirus. J. Pediatr. 1990, 116:1007-1008.
328. Schowengerdt K.O., et al. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 1997, 96:3549-3554.
329. Miller E., et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br. J. Obstet. Gynaecol. 1998, 105:14-18.
330. Nagel H.T., et al. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet. Gynecol. 2007, 109:42-47.
331. Gartner B., et al. Parvovirus B19 infections in pregnant women in day care facilities: health economic analysis of prohibition to employ seronegative women. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007, 50:1369-1378.
332. Ballou W.R., et al. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J. Infect. Dis. 2003, 187:675-678.
333. Bond P.R., et al. Intrauterine infection with human parvovirus (letter). Lancet 1986, 1:448-449.
334. Woernle C.H., et al. Human parvovirus B19 infection during pregnancy. J. Infect. Dis. 1987, 156:17-26.
335. Samra J.S., Obhrai M.S., Constantine G. Parvovirus infection in pregnancy. Obstet. Gynecol. 1989, 73:832-834.
336. Mortimer P.P., et al. Human parvovirus and the fetus. Lancet 1985, 2:1012.
337. Weiner C.P., Naides S.J. Fetal survival after human parvovirus B19 infection: spectrum of intrauterine response in a twin gestation. Am. J. Perinatol. 1992, 9:66.
338. Jordan J.A. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am. J. Obstet. Gynecol. 1996, 174:37-42.
339. Magro C.M., et al. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J. Reumatol. 2002, 29:1227-1235.
340. Douvoyiannis M., Litman N., Goldman L. Neurologic manifestations associated with parvovirus B19 infection. Clin. Infect. Dis. 2009, 48:1713-1723.
341. Guidi B., et al. Case of stroke in a 7-year-old male after parvovirus B19 infection. Pediatr. Neurol. 2003, 28:69-71.
342. Wierenga K.J., Serjeant B.E., Serjeant G.R. Cerebrovascular complications and parvovirus infection in homozygous sickle cell disease. J. Pediatr. 2001, 139:438-442.
343. Craze J.L., Salisbury A.J., Pike M.G. Prenatal stroke associated with maternal parvovirus infection. Dev. Med. Child Neurol. 1996, 38:84-85.
344. De Haan T.R., et al. Fetal stroke and congenital parvovirus B19 infection complicated by activated protein C resistance. Acta Paediatr. 2006, 95:863-867.